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ABSTRACT:  
 
Background: Cancer is an elusive neoplastic disease that claims the lives of many people 
around the world every year.  Though treatments have become more specific to the different 
types of cancer, the need for antineoplastic drugs that target cancer cells and leave normal cells 
unharmed, with little to no systemic toxicity remains, and rubredoxin might be such a tool.  
Rubredoxin is a small (53 amino acids), water soluble, non-heme iron electron transfer protein 
that contains an iron atom cofactor, which can be substituted with various cytotoxic transition 
metals such as nickel and cobalt with little or no effect on the protein.  Rubredoxin from the 
hyperthermophile Pyrococcus furiosus is thermostable and appears to have low immunogenicity.  
The focus of this project is to incorporate tumor-specific binding sequences at several modifiable 
sites on the protein as well as substitute the iron-center with cytotoxic metals.  Once a stable 
rubredoxin containing these characteristics is created, its effects and efficacy will be studied on 
specific cancer cells in vitro. 
 
Methods and results: Site-directed mutagenesis was used to incorporate a test epitope (E-tag) at 
the D20 position and an RGD-sequence at the carboxyl terminus respectively. The mutant 
proteins were purified using anion-exchange DEAE, size-exclusion G-75 Sephadex, and ceramic 
hydroxyapatite column chromatography. Proteins were analyzed using absorption spectroscopy, 
bicinchoninic acid (BCA) assay, SDS-PAGE, and electrospray ionization mass spectroscopy. 
Binding studies for the D20-Etag mutants will be done using dot blot and western blotting.  The 
metal content of the mutants was assessed using inductively-coupled plasma mass spectrometry. 
Lastly, integrin-stimulated Jurkat cancer cell lines will be incubated with wild-type rubredoxin, 
D20-Etag, D20-RGD, and the effect of these mutants will be assessed using western blotting and 
DNA fragmentation. 
 
Conclusions: The epitope E-tag was successfully incorporated between the D20 and N21 amino 
acid residues using site directed mutagenesis. The D20-Etag and D20-RGD mutant rubredoxin 
proteins were successfully expressed, purified, and analyzed. Currently, the iron-center is being 
substituted with different metals. Also, the effect of wild-type rubredoxin, D20-RGD, D20-Etag 
on integrin-stimulated Jurkat cells is being studied. This set of experiments will provide a further 
understanding and appreciation of rubredoxin as a potential targeted drug delivery system to 
cancer cells.  
 
 
  
 
 
